Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 16 of 16

Outcome	Group	Value	Spread	Units
Progression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause.	Double-Blind Phase - Nirogacestat	NA	95% Confidence Interval NA to NA	Months
Progression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause.	Double-Blind Phase - Placebo	15.1	95% Confidence Interval 8.4 to NA	Months
Objective Response Rate Using RECIST Version 1.1 Criteria.	Double-Blind Phase - Nirogacestat	41	95% Confidence Interval 29.8 to 53.8	percentage of participants
Objective Response Rate Using RECIST Version 1.1 Criteria.	Double-Blind Phase - Placebo	8	95% Confidence Interval 3.1 to 17.3	percentage of participants
Change From Baseline at Cycle 10 in the Brief Pain Inventory (BPI) Average Pain Intensity (API) Score.	Double-Blind Phase - Nirogacestat	-1.583	95% Confidence Interval -2.157 to -1.009	score on a scale
Change From Baseline at Cycle 10 in the Brief Pain Inventory (BPI) Average Pain Intensity (API) Score.	Double-Blind Phase - Placebo	-0.241	95% Confidence Interval -0.822 to 0.340	score on a scale
Change From Baseline at Cycle 10 in the GOunder/Desmoid Tumor Research Tumor Foundation (DTRF) DEsmoid Tumor Symptom Scale (DTSS) - Total Score	Double-Blind Phase - Nirogacestat	-1.110	95% Confidence Interval -1.569 to -0.651	score on a scale
Change From Baseline at Cycle 10 in the GOunder/Desmoid Tumor Research Tumor Foundation (DTRF) DEsmoid Tumor Symptom Scale (DTSS) - Total Score	Double-Blind Phase - Placebo	0.457	95% Confidence Interval -0.009 to 0.923	score on a scale
Change From Baseline in the GOunder/Desmoid Tumor Research Foundation (DTRF) DEsmoid Tumor Impact Scale (DTIS) - Physical Functioning Domain Score	Double-Blind Phase - Nirogacestat	-0.613	95% Confidence Interval -0.808 to -0.418	score on a scale
Change From Baseline in the GOunder/Desmoid Tumor Research Foundation (DTRF) DEsmoid Tumor Impact Scale (DTIS) - Physical Functioning Domain Score	Double-Blind Phase - Placebo	0.094	95% Confidence Interval -0.113 to 0.300	score on a scale
Change From Baseline at Cycle10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Scale.	Double-Blind Phase - Nirogacestat	2.935	95% Confidence Interval -3.115 to 8.985	score on a scale
Change From Baseline at Cycle10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Scale.	Double-Blind Phase - Placebo	-8.466	95% Confidence Interval -15.065 to -1.867	score on a scale
Change From Baseline at Cycle 10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Physical Functioning	Double-Blind Phase - Nirogacestat	9.143	95% Confidence Interval 5.619 to 12.668	score on a scale
Change From Baseline at Cycle 10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Physical Functioning	Double-Blind Phase - Placebo	-5.225	95% Confidence Interval -9.060 to -1.390	score on a scale
Change From Baseline at Cycle 10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Role Functioning.	Double-Blind Phase - Nirogacestat	13.293	95% Confidence Interval 7.080 to 19.506	score on a scale
Change From Baseline at Cycle 10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Role Functioning.	Double-Blind Phase - Placebo	-5.590	95% Confidence Interval -12.320 to 1.139	score on a scale

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03785964/results

API reference For AI assistants